Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
/ 352 items
#XY Event-Driven Stocks↓
CMS Reverses Course on Medicare Reimbursement for Orthofix Bone Growth Stimulators
Medicare reversed a pay cut for Orthofix devices, restoring revenue outlook and boosting the stock on improved earnings visibility.
Novartis to Acquire Myricx Bio for Up to $1.5 Billion to Bolster Next-Gen ADC Pipeline
Novartis is gaining B7-H3 and HER2 ADCs with innovative NMTi technology designed to overcome cancer resistance.
Seer CEO Omid Farokhzad Makes Unsolicited $2.45/Share Offer to Buy the Company
The Board will form a Special Committee to evaluate the offer.
United Therapeutics Acquires Thymmune Therapeutics for $300M to Advance Thymus-Based Regenerative Therapies
The deal accelerates United Therapeutics’ pipeline in immune restoration and transplant tolerance.
Arcturus Therapeutics Shares Surge on Thermo Fisher Collaboration for Cystic Fibrosis mRNA Therapy
Arcturus teams up with Thermo Fisher to develop a new cystic fibrosis mRNA drug, boosting shares on hopes for faster progress.